Search Results

You are looking at 1 - 10 of 77 items for :

  • "ductal carcinoma in situ" x
Clear All
Full access

Adam L. Cohen and John H. Ward

significantly different between groups. Table 1 Comparison of Randomized Trials of Adjuvant Tamoxifen for Ductal Carcinoma In Situ In a subgroup analysis, benefit seemed to be higher in women younger than 50 years (33% vs. 20% reduction), and the

Full access

Michael J. Hassett, Wei Jiang, Melissa E. Hughes, Stephen Edge, Sara H. Javid, Joyce C. Niland, Richard Theriault, Yu-Ning Wong, Deborah Schrag and Rinaa S. Punglia

As the incidence of ductal carcinoma in situ (DCIS) has increased, so has the number of DCIS survivors. 1 Most patients with DCIS are treated with breast-conserving surgery (BCS). 2 Radiation therapy (RT) and antiestrogen therapy (AET) have been

Full access

Stephen B. Edge and David G. Sheldon

ductal carcinoma in situ patients . Ann Surg Oncol 2000 ; 7 : 15 – 20 . 2 Cox CE Nguyen K Gray RJ . Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): Why map DCIS? Am Surg 2001 ; 67 : 513 – 519 . 3 Klauber

Full access

Rondi M. Kauffmann, Leanne Goldstein, Emily Marcinkowski, George Somlo, Yuan Yuan, Philip H.G. Ituarte, Laura Kruper, Leslie Taylor and Courtney Vito

Background Ductal carcinoma in situ (DCIS) is a premalignant breast lesion that has been increasingly diagnosed in the era of screening mammography, 1 and accounts for 20% to 25% of all new breast cancer diagnoses. 2 Marked atypia may be

Full access

Sara H. Javid, L. Christine Fang, Larissa Korde and Benjamin O. Anderson

In both the medical literature and lay press, a flurry of controversy has arisen surrounding the treatment and, more specifically, the potential overtreatment of ductal carcinoma in situ (DCIS). Since the advent of population-based screening

Full access

Puyao C. Li, Zilu Zhang, Angel M. Cronin and Rinaa S. Punglia

Background Women with a history of ductal carcinoma in situ (DCIS) are at increased risk for developing a second breast cancer (SBC) in either the ipsilateral or contralateral breast. 1 , 2 Many women receive breast-conserving surgery (BCS) with

Full access

Susan Lester

in situ component may be overgrown by the invasive carcinoma. The 20% to 30% of cases of breast cancer detected as CIS (predominantly ductal carcinoma in situ [DCIS], with fewer women with lobular carcinoma in situ [LCIS]) are likely to have

Full access

Brigette A. Davis, Jenerius A. Aminawung, Maysa M. Abu-Khalaf, Suzanne B. Evans, Kevin Su, Rajni Mehta, Shi-Yi Wang and Cary P. Gross

) invasive breast cancer irrespective of tumor size. Based on the 2009 guidelines, women with 1 to 3 positive axillary nodes were considered guideline-discordant. We excluded patients with ductal carcinoma in situ, localized HR+, node-negative, ≤5 mm

Full access

Sarah Asad, Carlos H. Barcenas, Richard J. Bleicher, Adam L. Cohen, Sara H. Javid, Ellis G. Levine, Nancy U. Lin, Beverly Moy, Joyce Niland, Antonio C. Wolff, Michael J. Hassett and Daniel G. Stover

at diagnosis compared with those who did not have rrTNBC (supplemental eTable 2). Figure 1. CONSORT diagram. Abbreviations: DCIS, ductal carcinoma in situ; HER2+, HER2-positive; HR+, hormone receptor–positive; LCIS, lobular carcinoma in situ; rrTNBC

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda L. Telli, John H. Ward, Rashmi Kumar and Dorothy A. Shead

ducts (ductal carcinoma in situ [DCIS]) or breast lobules (lobular carcinoma in situ). The management of patients with noninvasive or invasive breast cancer is complex and varied. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for